ZGNX Stock
Price Chart
ZGNX Financial and Trading Overview
| stock price | |
| Previous Close | 26.68 |
| Open | 26.6 |
| Bid | 0 x 1800 |
| Ask | 0 x 800 |
| Day's Range | 26.51 - 26.9 |
| 52 Week Range | 11.03 - 26.9 |
| Volume | 10.02M |
| Avg. Volume | 3.26M |
| Market Cap | 1.49B |
| Beta (5Y Monthly) | 1.17922 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.7 |
ZGNX Valuation Measures
| Enterprise Value | 760.86M |
| Trailing P/E | N/A |
| Forward P/E | -9.772894 |
| PEG Ratio (5 yr expected) | 0.02 |
| Price/Sales (ttm) | 23.49442 |
| Price/Book (mrq) | 6.653366 |
| Enterprise Value/Revenue | 11.966 |
| Enterprise Value/EBITDA | -3.636 |
Trading Information
Stock Price History
| Beta (5Y Monthly) | 1.17922 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 26.9 |
| 52 Week Low | 11.03 |
| 50-Day Moving Average | 23.18 |
| 200-Day Moving Average | 17.4 |
ZGNX Share Statistics
| Avg. Volume (3 month) | 3.26M |
| Avg. Daily Volume (10-Days) | 3.21M |
| Shares Outstanding | 55.99M |
| Float | 49.18M |
| Short Ratio | 9.14 |
| % Held by Insiders | 0.67% |
| % Held by Institutions | 107.24% |
| Shares Short | 5.89M |
| Short % of Float | 10.56% |
| Short % of Shares Outstanding | 10.52% |
Dividends & Splits
| Trailing Annual Dividend Rate | N/A |
| Trailing Annual Dividend Yield | N/A |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:8 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2020 |
| Most Recent Quarter (mrq) | September 30, 2021 |
| Next Fiscal Year End | December 31, 2022 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -343.92% |
| Gross Margin | -120.85% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -22.98% |
| Return on Equity (ttm) | -75.094% |
Income Statement
| Revenue (ttm) | 63.58M |
| Revenue Per Share (ttm) | 1.14 |
| Quarterly Revenue Growth (yoy) | 690.60% |
| Gross Profit (ttm) | -124901000 |
| EBITDA | -209231008 |
| Net Income Avi to Common (ttm) | -242700000 |
| Diluted EPS (ttm) | -4.349 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 343.02M |
| Total Cash Per Share (mrq) | 6.13 |
| Total Debt (mrq) | 166.58M |
| Total Debt/Equity (mrq) | 74.27 |
| Current Ratio (mrq) | 4.787 |
| Book Value Per Share (mrq) | 4.01 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -182324992 |
| Levered Free Cash Flow (ttm) | -96607752 |
Profile of
| Country | |
| State | CA |
| City | EmeryVille |
| Address | 5959 Horton Street |
| ZIP | 94608 |
| Phone | 510 550 8300 |
| Website | https://www.zogenix.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 218 |
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
Q&A For Stock
What is a current ZGNX stock price?
ZGNX stock price today per share is .
How to purchase stock?
You can buy ZGNX shares on the exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ?
The stock symbol or ticker of is ZGNX.
Which industry does the company belong to?
The industry is Biotechnology.
How many shares does have in circulation?
The max supply of shares is 0.
What is Price to Earnings Ratio (PE Ratio)?
PE Ratio is 0.00000000 now.
What was earnings per share over the trailing 12 months (TTM)?
EPS is 0 over the trailing 12 months.
Which sector does the company belong to?
The sector is Healthcare.
ZGNX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Biotechnology Total Retu XNBI | 4501.69 USD — |
-2.14
|
— — | 4479.13 USD — | 4578.05 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
- {{ link.label }} {{link}}